We are Minomic
Developer of novel prostate cancer diagnostics and therapeuticsDeveloping a new drug – Miltuximab®
We have developed the MiCheck® test for prostate cancer.
Trials
A series of clinical trials have shown MiCheck® gives much more accurate results than existing blood tests for prostate cancer.
Diagnosis
MiCheck® fills a major need in prostate cancer diagnostics for a highly specific test to follow on reported high PSA levels before invasive and expensive biopsies.
Validation
We are working on analytical validation for MiCheck® kits and on establishing MiCheck® as a Laboratory Developed Test available through labs certified for the Clinical Laboratory Improvements Amendment (CLIA).
Distribution
We are seeking partners around the world with sales, production, and distribution capabilities to take the MiCheck® test to their markets. Contact us about potential partnering.
Advances in therapeutics and imaging
Advanced trials are underway using our technologies to target tumors for treatment and imaging of cancers. Read more
Contact us to discuss registration and commercialization of future diagnostic imaging and therapeutic applications.
Headquarters in Australia
We are based in Sydney, adjacent to one of Australia’s leading universities, Macquarie University, and the Macquarie University Hospital, one of our key collaborators.
Our reach is global, through partnerships with universities, research institutes, and companies.
Our experience is backed up by independent experts in oncology, awards of multiple research grants and a major innovation prize, and investment backing of A$25 million to date.
Extensive intellectual property
Minomic owns an extensive patent estate protecting our distinctive technology. All the intellectual property relevant to our technology is owned by us.
Our investors and funding support
Minomic is an unlisted public company.
Over the past decade, Minomic has raised A$25m in funding. Investments have been made by MH Carnegie & Co through IIF (an Australian Government venture funding program) and by high net worth individuals.
Other sources of funding
include:
- an Australian Government Accelerating Commercialisation grant to help validate the MiCheck® test and support our rollout;
- Australian Government R&D Tax Incentives;
- a National Health and Medical Research Council Development Grant with QUT;
- ARC Hub award.
Contact us if you are interested in investing in the future of Minomic International.
Headquarters in Australia
Address
Suite 2, Ground Floor,
75 Talavera Road,
Macquarie Park, NSW 2113,
Australia
Phone
International +612 9850 4000
In Australia 02 9850 4000
Compare your time zone with Sydney here
Email
info@minomic.com
Finding Us
We are based in Sydney, adjacent to one of Australia’s leading universities, Macquarie University, and the Macquarie University Hospital, one of our key collaborators.
Headquarters of Minomic
